ACell announced that it has received a new 510(k) clearance from the US Food and Drug Administration (FDA) covering several devices in its Gentrix Surgical Matrix suite of products.
The clearance updates the indications for use for Gentrix Surgical Matrix, Gentrix Surgical Matrix Thin, and Gentrix Surgical Matrix Plus, adding important new claims to the product labeling.
Notably, these devices were shown to minimize unwanted attachment to surrounding visceral tissue. Further, ACell gained the specific indication for use of these three Gentrix devices in laparoscopic applications. Finally, ACell obtained clearance for a new hernia device configuration specifically indicated for reinforcement of hiatal hernia repairs.
“ACell continues to expand its presence in the hernia marketplace,” said Patrick McBrayer, President and CEO.
“This milestone from the FDA is another strategic building block in our objective to meet the needs of clinicians and patients with safe, cost-efficient, and clinically effective devices for complex hernia repair.”
“These clearances are especially impactful in supporting the use of Gentrix Surgical Matrix devices in minimally invasive hernia repairs. Surgeons performing such repairs know that if they heal with the formation of excess scar tissue, they are at risk for devastating complications, potential re-operations, and increased healthcare costs,” said Hazem Elariny, MD, Medical Director.
“Additionally, if a surgeon chooses to utilize a product in the intraperitoneal fashion, the demonstrated minimal attachment to surrounding tissue makes Gentrix an ideal option in these cases.”
The pre-clinical data used to support the new clearances will be presented in two posters at the Society of American Gastrointestinal and Endoscopic Surgeons Annual Meeting in Baltimore, Maryland April 3-6.
The first poster describes data that shows the minimization of tissue attachments to Gentrix when in contact with viscera. The study assessed the ability of two surgical grafts – Gentrix and SIS (small intestinal submucosa) – to minimize tissue attachments to the device in a rabbit model of intraperitoneal device placement, and concluded that the Gentrix devices performed similar or better than the SIS grafts.
A second poster will also be presented to describe the performance of Gentrix in a preclinical model of laparoscopic hiatal hernia repair.
Source: Company Press Release